Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology

Next Previous
Drug Profile

Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology

Alternative Names: 9-valent HPV recombinant vaccine - Shanghai Bovax Biotechnology; 9-valent HPV vaccine - Shanghai Bovax Biotechnology; 9vHPV vaccine

Latest Information Update: 26 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Bovax Biotechnology
  • Developer Chongqing Bovax Biopharmaceutical; Shanghai Bovax Biotechnology
  • Class Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Human papillomavirus infections

Most Recent Events

  • 11 Jul 2024 Shanghai Bovax Biotechnology initiates enrolment in a phase-III trial for Human papillomavirus infections (Prevention) in China (IM) (NCT06465914)
  • 20 Jun 2024 Shanghai Bovax Biotechnology plans a phase III trial for Human Papillomavirus infections (In adults, Prevention) in China (IM, Injection) in July 2024 (NCT06465914)
  • 12 Jun 2024 Shanghai Bovax Biotechnology plans a phase I trial for Human papillomavirus infections (In adolescents, In adults, In children, Prevention) in China (IM, Injection), in July 2024 (NCT06454175)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top